<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640831</url>
  </required_header>
  <id_info>
    <org_study_id>GH001-HV-101</org_study_id>
    <secondary_id>2018-003632-68</secondary_id>
    <nct_id>NCT04640831</nct_id>
  </id_info>
  <brief_title>Safety of GH001 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Dose-ranging Study of GH001 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GH Research Ireland Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GH Research Ireland Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the safety of GH001 (containing&#xD;
      5-methoxy-dimethyltryptamine; 5-MeO-DMT), and its dose-related psychoactive effects in&#xD;
      healthy volunteers.&#xD;
&#xD;
      The study will evaluate single, ascending doses of GH001 in Part A and an individualized&#xD;
      dosing regimen of GH001 in Part B.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Actual">October 4, 2019</completion_date>
  <primary_completion_date type="Actual">October 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A: Dose ranging in four dose groups Part B: One group with individualized dosing</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of GH001</measure>
    <time_frame>up to 7 days</time_frame>
    <description>The safety and tolerability of GH001 is judged by the Study Safety Group based on a combined analysis of reported adverse events, clinical observation, and safety laboratory analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The dose-related psychoactive effects of GH001 as evaluated by a Visual Analogue Scale</measure>
    <time_frame>Retrospectively assessed at 3 hours</time_frame>
    <description>Visual Analogue Scale scored from 0-100</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>GH001 dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GH001 dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GH001 dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GH001 dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GH001 Individualized Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 Methoxy N,N Dimethyltryptamine</intervention_name>
    <description>GH001 administered via inhalation</description>
    <arm_group_label>GH001 Individualized Dosing</arm_group_label>
    <arm_group_label>GH001 dose A</arm_group_label>
    <arm_group_label>GH001 dose B</arm_group_label>
    <arm_group_label>GH001 dose C</arm_group_label>
    <arm_group_label>GH001 dose D</arm_group_label>
    <other_name>GH001</other_name>
    <other_name>5-MeO-DMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a body mass index (BMI) in the range of 18.5 and 27.0 kg/m2 (inclusive);&#xD;
&#xD;
          -  Subject is in good general health in the opinion of the medical supervisor;&#xD;
&#xD;
          -  Subject is in good mental health in the opinion of the (clinical) psychologist as&#xD;
             determined by the intake interview;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has known allergies or hypersensitivity or any other contraindication to 5-MeO-DMT;&#xD;
&#xD;
          -  Has received any investigational medication within the last 1 month.&#xD;
&#xD;
          -  Has a medically significant condition, which renders the subject unsuitable for the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GH Research Clinical Team</last_name>
    <role>Study Director</role>
    <affiliation>GH Research Ireland Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>5-MeO-DMT</keyword>
  <keyword>5-methoxy-dimethyltryptamine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N,N-Dimethyltryptamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

